Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • M.D., Jefferson Medical College of Thomas Jefferson University 1990
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Klokker, Louise, Dorthe B. Berthelsen, Thasia Woodworth, Kathleen M. Andersen, Daniel E. Furst, Dan Devoe, Paula R. Williamson, et al. “Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials..” J Rheumatol 46, no. 9 (September 2019): 1173–78. https://doi.org/10.3899/jrheum.190196.
       Full Text  Link to Item
    • Lopez-Olivo, Maria A., José B. Negrón, Richard J. Zogala, Loreto Carmona, Karla Criner, Niti Goel, Laura Gonzalez-Lopez, et al. “Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis..” J Rheumatol 46, no. 9 (September 2019): 1164–67. https://doi.org/10.3899/jrheum.181076.
       Full Text  Link to Item
    • Duarte-García, Alí, Ying Ying Leung, Laura C. Coates, Dorcas Beaton, Robin Christensen, Ethan T. Craig, Maarten de Wit, et al. “Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report..” J Rheumatol 46, no. 8 (August 2019): 996–1005. https://doi.org/10.3899/jrheum.181089.
       Full Text  Link to Item
    • Orbai, Ana-Maria, Richard Holland, Ying Ying Leung, William Tillett, Niti Goel, Robin Christensen, Neil McHugh, et al. “PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials..” J Rheumatol 46, no. 8 (August 2019): 990–95. https://doi.org/10.3899/jrheum.181077.
       Full Text  Link to Item
    • Callis Duffin, Kristina, Dafna D. Gladman, Alice B. Gottlieb, and Niti Goel. “Prologue: 2018 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)..” J Rheumatol Suppl 95 (June 2019): 1–3. https://doi.org/10.3899/jrheum.190112.
       Full Text  Link to Item
    • Goel, Niti, Oliver FitzGerald, Dafna D. Gladman, Philip S. Helliwell, Arthur Kavanaugh, Walter P. Maksymowych, Philip J. Mease, Christopher T. Ritchlin, and Laura C. Coates. “GRAPPA 2018 Project Report..” J Rheumatol Suppl 95 (June 2019): 54–57. https://doi.org/10.3899/jrheum.190121.
       Full Text  Link to Item
    • Leung, Ying Ying, Ana-Maria Orbai, Alexis Ogdie, Laura C. Coates, Maarten de Wit, Kristina Callis Duffin, Lihi Eder, et al. “The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set..” J Rheumatol Suppl 95 (June 2019): 33–37. https://doi.org/10.3899/jrheum.190122.
       Full Text  Link to Item
    • Ratitch, Bohdana, Niti Goel, Craig Mallinckrodt, James Bell, Jonathan W. Bartlett, Geert Molenberghs, Pritibha Singh, Ilya Lipkovich, and Michael O’Kelly. “Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines..” Ther Innov Regul Sci, April 9, 2019. https://doi.org/10.1177/2168479019841316.
       Full Text  Link to Item
    • Ratitch, Bohdana, James Bell, Craig Mallinckrodt, Jonathan W. Bartlett, Niti Goel, Geert Molenberghs, Michael O’Kelly, Pritibha Singh, and Ilya Lipkovich. “Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice..” Ther Innov Regul Sci, April 4, 2019. https://doi.org/10.1177/2168479019838827.
       Full Text  Link to Item
    • Palominos, Penélope Esther, Laure Gossec, Sarah Kreis, César Luis Hinckel, Rafael Mendonça da Silva Chakr, Ana Laura Didonet Moro, Willemina Campbell, et al. “The effects of cultural background on patient-perceived impact of psoriatic arthritis - a qualitative study conducted in Brazil and France..” Adv Rheumatol 58, no. 1 (October 22, 2018). https://doi.org/10.1186/s42358-018-0036-6.
       Full Text  Link to Item
    • Goel, Niti, Denis O’Sullivan, Maarten de Wit, Chris A. Lindsay, Heidi Bertheussen, John Latella, Jeffrey Chau, et al. “The Patient Research Partner Network Matures: A Report from the GRAPPA 2017 Annual Meeting..” J Rheumatol Suppl 94 (June 2018): 52–53. https://doi.org/10.3899/jrheum.180138.
       Full Text  Link to Item
    • Goel, Niti, Denis O’sullivan, Maarten de Wit, Chris A. Lindsay, Heidi Bertheussen, John Latella, Jeffrey Chau, et al. “The Patient Research Partner Network Matures: A Report from the GRAPPA 2017 Annual Meeting.” Journal of Rheumatology 45, no. 6 (June 1, 2018): 52–53. https://doi.org/10.3899/jrheum.l80138.
       Full Text  Link to Item
    • Holland, Richard, William Tillett, Alexis Ogdie, Ying Y. Leung, Dafna D. Gladman, Kristina Callis Duffin, Laura C. Coates, et al. “Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting..” J Rheumatol Suppl 94 (June 2018): 17–25. https://doi.org/10.3899/jrheum.180142.
       Full Text  Link to Item
    • Højgaard, Pil, Louise Klokker, Ana-Maria Orbai, Kim Holmsted, Else M. Bartels, Ying Ying Leung, Niti Goel, et al. “A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative..” Semin Arthritis Rheum 47, no. 5 (April 2018): 654–65. https://doi.org/10.1016/j.semarthrit.2017.09.002.
       Full Text  Link to Item
    • Hillson, Jan, Tim Mant, Molly Rosano, Carolyn Huntenburg, Mehrshid Alai-Safar, Siddhesh Darne, Donna Palmer, et al. “Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects..” Pharmacol Res Perspect 6, no. 1 (February 2018). https://doi.org/10.1002/prp2.380.
       Full Text  Open Access Copy  Link to Item
    • Klokker, Louise, Peter Tugwell, Daniel E. Furst, Dan Devoe, Paula Williamson, Caroline B. Terwee, Maria E. Suarez-Almazor, et al. “Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group..” J Rheumatol 44, no. 12 (December 2017): 1916–19. https://doi.org/10.3899/jrheum.161105.
       Full Text  Link to Item
    • Rasch, Linda A., Maarten Boers, Catherine L. Hill, Marieke Voshaar, Wijnanda Hoogland, Maarten de Wit, Caroline Flurey, et al. “Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016..” J Rheumatol 44, no. 12 (December 2017): 1889–93. https://doi.org/10.3899/jrheum.161111.
       Full Text  Link to Item
    • Zamora, Natalia V., Robin Christensen, Niti Goel, Louise Klokker, Maria A. Lopez-Olivo, Lars E. Kristensen, Loreto Carmona, Vibeke Strand, Jeffrey R. Curtis, and Maria E. Suarez-Almazor. “Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report..” J Rheumatol 44, no. 12 (December 2017): 1894–98. https://doi.org/10.3899/jrheum.161108.
       Full Text  Link to Item
    • Petkovic, Jennifer, Jennifer L. Barton, Caroline Flurey, Niti Goel, Christie M. Bartels, Cheryl Barnabe, Maarten P. T. de Wit, et al. “Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group..” J Rheumatol 44, no. 11 (November 2017): 1727–33. https://doi.org/10.3899/jrheum.160975.
       Full Text  Link to Item
    • Orbai, Ana-Maria, Maarten de Wit, Philip J. Mease, Kristina Callis Duffin, Musaab Elmamoun, William Tillett, Willemina Campbell, et al. “Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016..” J Rheumatol 44, no. 10 (October 2017): 1522–28. https://doi.org/10.3899/jrheum.160904.
       Full Text  Link to Item
    • Goel, Niti, Denis O’Sullivan, Ingrid Steinkoenig, Jana James, Chris A. Lindsay, Laura C. Coates, John Latella, et al. “Tackling Patient Centricity: A Report from the GRAPPA 2016 Annual Meeting..” J Rheumatol 44, no. 5 (May 2017): 703–5. https://doi.org/10.3899/jrheum.170152.
       Full Text  Link to Item
    • Jadon, Deepak R., Dafna D. Gladman, Philip J. Mease, Oliver FitzGerald, Vinod Chandran, Niti Goel, Cheryl F. Rosen, et al. “Proceedings of the GRAPPA 2016 Retreat..” J Rheumatol 44, no. 5 (May 2017): 668–73. https://doi.org/10.3899/jrheum.170141.
       Full Text  Link to Item
    • Ogdie, Alexis, Maarten de Wit, Kristina Callis Duffin, Willemina Campbell, Jeffrey Chau, Laura C. Coates, Lihi Eder, et al. “Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group..” J Rheumatol 44, no. 5 (May 2017): 697–700. https://doi.org/10.3899/jrheum.170150.
       Full Text  Link to Item
    • Tuyl, Lilian H. D. van, Martina Sadlonova, Sarah Hewlett, Bev Davis, Caroline Flurey, Niti Goel, Laure Gossec, et al. “The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission..” Ann Rheum Dis 76, no. 5 (May 2017): 855–61. https://doi.org/10.1136/annrheumdis-2016-209835.
       Full Text  Link to Item
    • Orbai, Ana-Maria, Maarten de Wit, Philip Mease, Judy A. Shea, Laure Gossec, Ying Ying Leung, William Tillett, et al. “International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials..” Ann Rheum Dis 76, no. 4 (April 2017): 673–80. https://doi.org/10.1136/annrheumdis-2016-210242.
       Full Text  Link to Item
    • Goel, Niti, and Kamali Chance. “Biosimilars in rheumatology: understanding the rigor of their development..” Rheumatology (Oxford) 56, no. 2 (February 2017): 187–97. https://doi.org/10.1093/rheumatology/kew206.
       Full Text  Link to Item
    • Orbai, Ana-Maria, Philip J. Mease, Maarten de Wit, Umut Kalyoncu, Willemina Campbell, William Tillett, Lihi Eder, et al. “Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting..” J Rheumatol 43, no. 5 (May 2016): 965–69. https://doi.org/10.3899/jrheum.160116.
       Full Text  Link to Item
    • Wit, Maarten de, Willemina Campbell, Laura C. Coates, Dafna D. Gladman, Jana James, Chris A. Lindsay, Roland MacDonald, et al. “Let's Talk about Inclusion: A Report on Patient Research Partner Involvement in the GRAPPA 2015 Annual Meeting..” J Rheumatol 43, no. 5 (May 2016): 970–73. https://doi.org/10.3899/jrheum.160117.
       Full Text  Link to Item
    • Combe, Bernard, Daniel E. Furst, Edward C. Keystone, Désirée van der Heijde, Kristel Luijtens, Lucian Ionescu, Niti Goel, and Paul Emery. “Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials..” Arthritis Care Res (Hoboken) 68, no. 3 (March 2016): 299–307. https://doi.org/10.1002/acr.22676.
       Full Text  Link to Item
    • Tuyl, Lilian H. van, Martina Sadlonova, Bev Davis, Caroline Flurey, Niti Goel, Sarah E. Hewlett, Catherine L. Hill, et al. “Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12..” J Rheumatol 43, no. 1 (January 2016): 203–7. https://doi.org/10.3899/jrheum.141113.
       Full Text  Link to Item
    • Petkovic, Jennifer, Jonathan Epstein, Rachelle Buchbinder, Vivian Welch, Tamara Rader, Anne Lyddiatt, Rosemary Clerehan, et al. “Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome Measures..” J Rheumatol 42, no. 12 (December 2015): 2448–59. https://doi.org/10.3899/jrheum.141168.
       Full Text  Link to Item
    • Tillett, William, Lihi Eder, Niti Goel, Maarten De Wit, Dafna D. Gladman, Oliver FitzGerald, Willemina Campbell, et al. “Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014..” J Rheumatol 42, no. 11 (November 2015): 2198–2203. https://doi.org/10.3899/jrheum.141156.
       Full Text  Link to Item
    • Christensen, Robin, Lara J. Maxwell, Peter Jüni, David Tovey, Paula R. Williamson, Maarten Boers, Niti Goel, et al. “Consensus on the Need for a Hierarchical List of Patient-reported Pain Outcomes for Metaanalyses of Knee Osteoarthritis Trials: An OMERACT Objective..” J Rheumatol 42, no. 10 (October 2015): 1971–75. https://doi.org/10.3899/jrheum.141384.
       Full Text  Link to Item
    • Maxwell, Lara J., George A. Wells, Lee S. Simon, Philip G. Conaghan, Shawna Grosskleg, Kerry Scrivens, Dorcas E. Beaton, et al. “Current State of Reporting Pain Outcomes in Cochrane Reviews of Chronic Musculoskeletal Pain Conditions and Considerations for an OMERACT Research Agenda..” J Rheumatol 42, no. 10 (October 2015): 1934–42. https://doi.org/10.3899/jrheum.141423.
       Full Text  Link to Item
    • Cummins, G., N. Goel, J. Downing, and L. V. Tuyl. “Rapid Acquisition of Data on The Patient Perspective In Rheumatoid Arthrtis Through A Digital Portal.” Value in Health 18, no. 3 (May 2015): A165–A165. https://doi.org/10.1016/j.jval.2015.03.955.
       Full Text
    • De Wit, M., W. Campbell, A. M. Orbai, W. Tillett, O. Fitzgerald, D. D. Gladman, C. A. Lindsay, et al. “Building bridges between researchers and patient research partners: A report from the grappa 2014 annual meeting.” Journal of Rheumatology 42, no. 6 (January 1, 2015): 1021–26. https://doi.org/10.3899/jrheum.150123.
       Full Text
    • Tillett, W., L. Eder, N. Goel, M. De Wit, A. Ogdie, A. M. Orbai, W. Campbell, et al. “Review of the psoriatic arthritis working group at OMERACT 12: A report from the GRAPPA 2014 annual meeting.” Journal of Rheumatology 42, no. 6 (January 1, 2015): 1048–51. https://doi.org/10.3899/jrheum.150131.
       Full Text
    • Goel, Niti, and Kamali Charnce. “The Biosimilar Landscape: A Systematic Review of Its Current Status..” Arthritis & Rheumatology 66 (October 1, 2014): S662–S662.
       Link to Item
    • Wit, Maarten de, Willemina Campbell, Oliver FitzGerald, Dafna D. Gladman, Phillip S. Helliwell, Jana James, Chris Lindsay, et al. “Patient participation in psoriasis and psoriatic arthritis outcome research: a report from the GRAPPA 2013 Annual Meeting..” J Rheumatol 41, no. 6 (June 2014): 1206–11. https://doi.org/10.3899/jrheum.140171.
       Full Text  Link to Item
    • Coates, Laura C., Oliver FitzGerald, Philip J. Mease, Dafna D. Gladman, Vibeke Strand, Niti Goel, Ina Campbell, Gerald Krueger, Neil J. McHugh, and Philip S. Helliwell. “Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11..” J Rheumatol 41, no. 4 (April 2014): 782–91. https://doi.org/10.3899/jrheum.131250.
       Full Text  Link to Item
    • Weinblatt, Michael E., Roy Fleischmann, Tom W. J. Huizinga, Paul Emery, Janet Pope, Elena M. Massarotti, Ronald F. van Vollenhoven, et al. “Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study..” Rheumatology (Oxford) 51, no. 12 (December 2012): 2204–14. https://doi.org/10.1093/rheumatology/kes150.
       Full Text  Link to Item
    • Keystone, Edward C., Bernard Combe, Josef Smolen, Vibeke Strand, Niti Goel, Ronald van Vollenhoven, Philip Mease, et al. “Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial..” Rheumatology (Oxford) 51, no. 9 (September 2012): 1628–38. https://doi.org/10.1093/rheumatology/kes082.
       Full Text  Link to Item
    • Choy, Ernest, Frank McKenna, Jiri Vencovsky, Robert Valente, Niti Goel, Brenda Vanlunen, Owen Davies, Hans-Detlev Stahl, and Rieke Alten. “Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX..” Rheumatology (Oxford) 51, no. 7 (July 2012): 1226–34. https://doi.org/10.1093/rheumatology/ker519.
       Full Text  Link to Item
    • Miossec, P., C. L. Verweij, L. Klareskog, C. Pitzalis, A. Barton, F. Lekkerkerker, S. Reiter, et al. “Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies..” Ann Rheum Dis 70, no. 10 (October 2011): 1713–18. https://doi.org/10.1136/ard.2011.154252.
       Full Text  Link to Item
    • Smolen, Josef S., Maarten Boers, Eric C. Abadie, Ferdinand C. Breedveld, Paul Emery, Thomas Bardin, Niti Goel, et al. “Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis..” Rheumatology (Oxford) 50, no. 10 (October 2011): 1732–36. https://doi.org/10.1093/rheumatology/keq413.
       Full Text  Link to Item
    • Alten, Rieke, Christof Pohl, Ernest H. Choy, Robin Christensen, Daniel E. Furst, Sarah E. Hewlett, Amye Leong, et al. “Developing a Construct to Evaluate Flares in Rheumatoid Arthritis: A Conceptual Report of the OMERACT RA Flare Definition Working Group.” Journal of Rheumatology 38, no. 8 (August 1, 2011): 1745–50. https://doi.org/10.3899/jrheum.110400.
       Full Text  Link to Item
    • Curtis, Jeffrey R., L. Chen, K. Luijtens, I. Navarro-Millan, N. Goel, L. Gervitz, and M. Weinblatt. “Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data..” Arthritis Rheum 63, no. 8 (August 2011): 2203–8. https://doi.org/10.1002/art.30387.
       Full Text  Link to Item
    • Smolen, Josef S., Maarten Boers, Eric C. Abadie, Ferdinand C. Breedveld, Paul Emery, Thomas Bardin, Niti Goel, et al. “Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA..” Curr Med Res Opin 27, no. 2 (February 2011): 315–25. https://doi.org/10.1185/03007995.2010.542135.
       Full Text  Link to Item
    • Bruyere, O., J. A. Kanis, M. -. E. Ibar-Abadie, N. Alsayed, M. L. Brandi, N. Burlet, D. L. Cahall, et al. “The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES)..” Osteoporos Int 21, no. 5 (May 2010): 713–22. https://doi.org/10.1007/s00198-010-1190-9.
       Full Text  Link to Item
    • Goel, Niti, and Sue Stephens. “Certolizumab pegol..” Mabs 2, no. 2 (March 2010): 137–47. https://doi.org/10.4161/mabs.2.2.11271.
       Full Text  Link to Item
    • McNearney, Terry A., Sonya E. Hunnicutt, Michael Fischbach, Alan W. Friedman, Martha Aguilar, Chul W. Ahn, John D. Reveille, et al. “Perceived functioning has ethnic-specific associations in systemic sclerosis: another dimension of personalized medicine..” J Rheumatol 36, no. 12 (December 2009): 2724–32. https://doi.org/10.3899/jrheum.090295.
       Full Text  Link to Item
    • Fleischmann, R., J. Vencovsky, R. F. van Vollenhoven, D. Borenstein, J. Box, G. Coteur, N. Goel, H. -. P. Brezinschek, A. Innes, and V. Strand. “Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study..” Ann Rheum Dis 68, no. 6 (June 2009): 805–11. https://doi.org/10.1136/ard.2008.099291.
       Full Text  Link to Item
    • Heijde, Desiree van der, Michael Weinblatt, Robert Landewe, Niti Goel, and Roy Fleischmann. “RAPID INHIBITION OF PROGRESSION OF STRUCTURAL DAMAGE WITH CERTOLIZUMAB PEGOL, A NOVEL SC PEGYLATED, FC-FREE ANTI-TNF.” Rheumatology 48 (April 1, 2009): I18–I18.
       Link to Item
    • Compston, J., D. M. Reid, J. Boisdron, M. L. Brandi, N. Burlet, D. Cahall, P. D. Delmas, et al. “Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: An update from the Group for the Respect of Ethics and Excellence in Science (Osteoporosis International DOI: 10.1007/s00198-008-0670-7).” Osteoporosis International 20, no. 3 (March 1, 2009): 497–98. https://doi.org/10.1007/s00198-008-0735-7.
       Full Text
    • Compston, J., D. M. Reid, J. Boisdron, M. -. L. Brandi, N. Burlet, D. Cahall, P. D. Delmas, et al. “Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science..” Osteoporos Int 19, no. 9 (September 2008): 1247–50. https://doi.org/10.1007/s00198-008-0670-7.
       Full Text  Link to Item
    • McNearney, Terry A., John D. Reveille, Michael Fischbach, Alan W. Friedman, Jeffrey R. Lisse, Niti Goel, Filemon K. Tan, et al. “Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors..” Arthritis Rheum 57, no. 2 (March 15, 2007): 318–26. https://doi.org/10.1002/art.22532.
       Full Text  Link to Item
    • McNearney, Terry A., Angela J. Shepherd, Ajoy Chhabra, and Niti Goel. “Primary care house staff attitudes toward osteoporosis management..” South Med J 99, no. 5 (May 2006): 461–66. https://doi.org/10.1097/01.smj.0000216495.79818.eb.
       Full Text  Link to Item
    • King, Alison B., K. G. Saag, R. T. Burge, M. Pisu, and N. Goel. “Fracture Reduction Affects Medicare Economics (FRAME): impact of increased osteoporosis diagnosis and treatment..” Osteoporos Int 16, no. 12 (December 2005): 1545–57. https://doi.org/10.1007/s00198-005-1869-5.
       Full Text  Link to Item
    • Hendiani, J Amir, Karin N. Westlund, Nada Lawand, Niti Goel, Jeffrey Lisse, and Terry McNearney. “Mechanical sensation and pain thresholds in patients with chronic arthropathies..” J Pain 4, no. 4 (May 2003): 203–11. https://doi.org/10.1016/s1526-5900(03)00557-1.
       Full Text  Link to Item
    • Sairam, S., N. Goel, J. Lisse, and T. McNearney. “Pericardial effusion and cardiomyopathy following arthritis with parvovirus B19 infection: response to intravenous immunoglobulin..” J Clin Rheumatol 7, no. 5 (October 2001): 346–49. https://doi.org/10.1097/00124743-200110000-00020.
       Full Text  Link to Item
    • Bali, D., S. Gourley, D. D. Kostyu, N. Goel, I. Bruce, A. Bell, D. J. Walker, et al. “Genetic analysis of multiplex rheumatoid arthritis families..” Genes Immun 1, no. 1 (September 1999): 28–36. https://doi.org/10.1038/sj.gene.6363635.
       Full Text  Link to Item
    • Friedman, A. W., G. S. Alarcón, G. McGwin, K. V. Straaton, J. Roseman, N. Goel, and J. D. Reveille. “Systemic lupus erythematosus in three ethnic groups. IV. Factors associated with self-reported functional outcome in a large cohort study. LUMINA Study Group. Lupus in Minority Populations, Nature versus Nurture..” Arthritis Care Res 12, no. 4 (August 1999): 256–66. https://doi.org/10.1002/1529-0131(199908)12:4<256::aid-art4>3.0.co;2-g.
       Full Text  Link to Item
    • Reisner, B. S., J. DiBlasi, and N. Goel. “Comparison of an enzyme immunoassay to an indirect fluorescent immunoassay for the detection of antinuclear antibodies..” Am J Clin Pathol 111, no. 4 (April 1999): 503–6. https://doi.org/10.1093/ajcp/111.4.503.
       Full Text  Link to Item
    • Goel, N., T. L. Ortel, D. Bali, J. P. Anderson, I. S. Gourley, H. Smith, C. A. Morris, et al. “Familial antiphospholipid antibody syndrome: criteria for disease and evidence for autosomal dominant inheritance..” Arthritis Rheum 42, no. 2 (February 1999): 318–27. https://doi.org/10.1002/1529-0131(199902)42:2<318::AID-ANR15>3.0.CO;2-5.
       Full Text  Link to Item
    • McNearney, T., N. Goel, J. Lisse, D. Speegle, B. Baethge, and K. Westlund. “Temporal fluctuations in excitatory and inhibitory amino acid profiles of synovial fluids derived from patients with arthropathies..” Journal of Investigative Medicine 47, no. 2 (February 1, 1999): 109A-109A.
       Link to Item
    • Reveille, J. D., K. A. Johnston, C. Ahn, F. K. Tan, A. W. Friedman, N. Goel, J. M. Moulds, G. McGwinn, J. Roseman, and G. S. Alarcon. “Genetic predictors of disease damage and activity early in SLE among patients from three ethnic groups..” Arthritis and Rheumatism 41, no. 9 (September 1, 1998): S283–S283.
       Link to Item
    • Alarcón, G. S., J. Roseman, A. A. Bartolucci, A. W. Friedman, J. M. Moulds, N. Goel, K. V. Straaton, and J. D. Reveille. “Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course. LUMINA Study Group. Lupus in minority populations, nature versus nurture..” Arthritis Rheum 41, no. 7 (July 1998): 1173–80. https://doi.org/10.1002/1529-0131(199807)41:7<1173::AID-ART5>3.0.CO;2-A.
       Full Text  Link to Item
    • Alarcón, G. S., J. Roseman, A. A. Bartolucci, A. W. Friedman, J. M. Moulds, N. Goel, K. V. Straaton, and J. D. Reveille. “Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course.” Arthritis and Rheumatism 41, no. 7 (July 1, 1998): 1173–80. https://doi.org/10.1002/1529-0131(199807)41:7<1173::AID-ART5>3.0.CO;2-A.
       Full Text
    • Goel, N. “Antiphospholipid antibody syndrome: current concepts..” Hosp Pract (1995) 33, no. 2 (February 15, 1998): 129-passim. https://doi.org/10.1080/21548331.1998.11443641.
       Full Text  Link to Item
    • Alarcon, G. S., A. A. Bartolucci, J. M. Roseman, A. W. Friedman, K. V. Straaton, N. Goel, N. M. Burst, and J. D. Reveille. “Predictors of disease damage early in the course of SLE among patients from different ethnic groups..” Arthritis and Rheumatism 40, no. 9 (September 1, 1997): 776–776.
       Link to Item
    • Bali, D., I. S. Gourley, D. Kostyu, I. Bruce, A. Bell, N. Goel, D. K. Zhu, C. Amos, and M. F. Seldin. “Genetic analysis of multiplex rheumatoid arthritis families..” Arthritis and Rheumatism 39, no. 9 (September 1, 1996): 279–279.
       Link to Item
    • Elkon, K. B., P. H. Krammer, D. H. Lynch, N. Goel, and M. F. Seldin. “Elevated levels of soluble Fas in systemic lupus erythematosus: Reply.” Arthritis and Rheumatism 39, no. 9 (September 1, 1996): 1613–14.
       Link to Item
    • Goel, N., D. T. Ulrich, E. W. St Clair, J. A. Fleming, D. H. Lynch, and M. F. Seldin. “Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease..” Arthritis Rheum 38, no. 12 (December 1995): 1738–43. https://doi.org/10.1002/art.1780381206.
       Full Text  Link to Item
    • GOEL, N., E. W. STCLAIR, J. A. FLEMING, and M. F. SELDIN. “LACK OF CORRELATION OF SERUM-SOLUBLE FAS LEVELS AND AUTOIMMUNE-DISEASE.” Arthritis and Rheumatism 38, no. 9 (September 1, 1995): 682–682.
       Link to Item

  • Conference Papers

    • Duarte-Garcia, Ali, Lihi Eder, Niti Goel, Maarten de Wit, Dafna D. Gladman, Oliver Fitzgerald, Philip J. Mease, et al. “SAT0395 RESPONSIVENESS AND CLINICAL TRIAL DISCRIMINATION OF SWOLLEN AND TENDER JOINT COUNTS FOR THE MEASUREMENT OF MSK DISEASE ACTIVITY IN PSORIATIC ARTHRITIS.” In Saturday, 15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. https://doi.org/10.1136/annrheumdis-2019-eular.1659.
       Full Text
    • Furie, Richard, Darrin Bomba, Maria Dall’era, Massiel Prieto, Janet Anderl, Jinhai Wang, Christopher Kirk, and Niti Goel. “FRI0196 TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 2 COHORTS OF AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL.” In Poster Presentations. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. https://doi.org/10.1136/annrheumdis-2019-eular.1955.
       Full Text
    • Duarte-Garcia, Ali, Lihi Eder, Alisa Stephens-Shields, Niti Goel, Maarten de Wit, Dafna D. Gladman, Oliver FitzGerald, et al. “Construct Validity of the Swollen and Tender Joint Counts for the Measurement of MSK Disease Activity in Psoriatic Arthritis.” In Arthritis & Rheumatology, Vol. 70. WILEY, 2018.
       Link to Item
    • Duarte-Garcia, Ali, Lihi Eder, Niti Goel, Robin Christensen, Maarten de Wit, Oliver FitzGerald, Dafna D. Gladman, et al. “The 66/68 Joint Count for the Measurement of MSK Disease Activity/Peripheral Joint Activity in Psa: A Grappa-Omeract Working Group Initiative.” In Arthritis & Rheumatology, Vol. 70. WILEY, 2018.
       Link to Item
    • Holland, Richard, Robin Christensen, Niti Goel, Pil Hoejgaard, William Tillett, Laure Gossec, Maarten de Wit, et al. “Psoriatic Arthritis Impact of Disease (PsAID12) Was Provisionally Endorsed at Omeract 2018 As Core Instrument to Measure Psoriatic Arthritis-Specific Health-Related Quality of Life in Randomized Controlled Trials and Longitudinal Observational Studies.” In Arthritis & Rheumatology, Vol. 70. WILEY, 2018.
       Link to Item
    • Carvalho, P. D., N. Goel, M. Voshaar, M. Boers, and J. A. P. D. Silva. “SAT0241 Patients’ perspective on the efficacy and risks of glucocorticoids in ra – an initiative under the gloria project.” In Saturday, 16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. https://doi.org/10.1136/annrheumdis-2018-eular.7041.
       Full Text
    • Goel, Niti, Stephen Wax, Amy Kao, Russell Reeve, and Marsha Mackey. “Quantiferon Testing in a Clinical Trial of Systemic Lupus Erythematosus.” In Arthritis & Rheumatology, Vol. 69. WILEY, 2017.
       Link to Item
    • Klokker, L., T. Woodworth, D. E. Furst, P. Tugwell, D. Devoe, P. Williamson, C. B. Terwee, et al. “THU0677 Outcome measurement instruments for safety in rheumatology: a scoping review of available instruments to inform the omeract safety working group.” In Poster Presentations. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. https://doi.org/10.1136/annrheumdis-2017-eular.6141.
       Full Text
    • Goel, Niti, Brandon Barrett, Ann Duncan, Margaret-Beth Gallagher, and Marsha Mackey. “Randomized Clinical Trials of Systemic Lupus Erythematosus: Evaluating Differences in the Enrolled Populations.” In Arthritis & Rheumatology, Vol. 68. WILEY, 2016.
       Link to Item
    • Hillson, Jan, Tim Mant, Tanmoy Ganguly, William Avery, Molly Rosano, Carolyn Huntenburg, Donna Palmer, et al. “Assessment of Comparative Immunogenicity in Biosimilar Development: Immunogenicity and Pharmacokinetics Following a Single Dose of M923, a Proposed Biosimilar for Reference Adalimumab (HUMIRA (R)), Compared with US- and EU-Sourced Reference Adalimumab in Healthy Subjects.” In Arthritis & Rheumatology, Vol. 68. WILEY, 2016.
       Link to Item
    • Orbai, Ana-Maria, Maarten de Wit, Philip J. Mease, Judy A. Shea, Laure Gossec, Ying Ying Leung, William Tillett, et al. “International Patient and Physician Consensus on Psoriatic Arthritis Outcomes for Clinical Trials.” In Arthritis & Rheumatology, Vol. 68, 2016.
       Link to Item
    • Wit, Maarten de, Alexis Ogdie, Willemina Campbell, Philip Mease, Niti Goel, Laure Gossec, Ying Y. Leung, et al. “Feasibility and added value of meaningful patient involvement in the development of a core outcome set for psoriatic arthritis.” In Quality of Life Research, 25:55–56. SPRINGER, 2016.
       Link to Item
    • Zamora, Natalia V., Maria A. Lopez-Olivo, Robin Christensen, Niti Goel, Lars Erik Kristensen, Vibeke Strand, Jeffrey R. Curtis, Beverly Shea, and Maria Suarez-Almazor. “Environmental Scan of Rheumatoid Arthritis Patient Registries Around the World: An Omeract Initiative.” In Arthritis & Rheumatology, Vol. 68. WILEY, 2016.
       Link to Item
    • Goel, N., B. Barrett, A. Duncan, M. -. B. Gallagher, and M. Mackey. “FRI0346 Evaluating Differences in The Enrolled Populations of Randomized Clinical Trials of Systemic Lupus Erythematosus.” In Annals of the Rheumatic Diseases, 75:560.1-560. BMJ, 2016. https://doi.org/10.1136/annrheumdis-2016-eular.4457.
       Full Text
    • Goel, N., F. Eisenberg, M. Barboza, D. Campion, and K. Bibeau. “AB1035 Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Registries: A Qualitative Analysis of Data in clinicaltrials.gov.” In Annals of the Rheumatic Diseases, 75:1256.1-1256. BMJ, 2016. https://doi.org/10.1136/annrheumdis-2016-eular.4398.
       Full Text
    • Hillson, J., T. Mant, T. Ganguly, M. Rosano, C. Huntenburg, M. Alai-Safar, S. Darne, et al. “FRI0182 A Single Dose Study Comparing Pharmacokinetics, Safety, and Immunogenicity of M923 (A Proposed Biosimilar To Adalimumab), US-Sourced Adalimumab, and EU-Sourced Adalimumab in Healthy Subjects.” In Annals of the Rheumatic Diseases, 75:495.3-496. BMJ, 2016. https://doi.org/10.1136/annrheumdis-2016-eular.3706.
       Full Text
    • Goel, N., G. Cummins, J. Downing, and L. van Tuyl. “FRI0362 Rapid Acquisition of Data on the Patient Perspective in Rheumatoid Arthrtis Through a Digital Portal.” In Annals of the Rheumatic Diseases, 74:557.2-557. BMJ, 2015. https://doi.org/10.1136/annrheumdis-2015-eular.2290.
       Full Text
    • Tuyl, L. H. van, M. Sadlonova, S. Hewlett, B. Davis, C. Flurey, N. Goel, L. Gossec, et al. “FRI0047 The Patient Perspective on Absence of Disease Activity in Rheumatoid Arthritis: A Survey to Identify Key Domains of Patient Perceived Remission.” In Annals of the Rheumatic Diseases, 74:435.3-436. BMJ, 2015. https://doi.org/10.1136/annrheumdis-2015-eular.2238.
       Full Text
    • Klokker, Louise, Lara J. Maxwell, Peter Juni, David Tovey, Paula R. Williamson, Maarten Boers, Niti Goel, et al. “Consensus on the need for a hierarchical list of patient-reported pain outcomes for meta-analyses of knee osteoarthritis trials.” In Trials, Vol. 16, 2015.
       Link to Item
    • Goel, N., E. van Rijen, J. Hillier, R. Hepburn, and A. Duncan. “FRI0440 Lupus Clinical Trials: A Systematic Review of the Landscape and Opportunities for Improvement.” In Annals of the Rheumatic Diseases, 73:546.2-547. BMJ, 2014. https://doi.org/10.1136/annrheumdis-2014-eular.5307.
       Full Text
    • Alten, Rieke, Christof Pohl, Ernest H. Choy, Robin Christensen, Daniel E. Furst, Sarah E. Hewlett, Amye Leong, et al. “Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group..” In J Rheumatol, 38:1745–50, 2011. https://doi.org/10.3899/jrheum.110400.
       Full Text  Link to Item
    • Keystone, Edward, Desiree Van der Heijde, Joseph Smolen, Michael Weinblatt, Tore Kvien, Vibeke Strand, Zainab Ansari, Niti Goel, and Bernard Combe. “Open-Label Certolizumab Pegol Is Effective In Patients Who Withdrew From Double-Blind Treatment Due To Non-Response.” In Journal of Rheumatology, 37:1333–1333. J RHEUMATOL PUBL CO, 2010.
       Link to Item
    • Keystone, Edward, Roy Fleischmann, Joseph Smolen, Vibeke Strand, Robert Landewe, Bernard Combe, Philip Mease, Zainab Ansari, Niti Goel, and Desiree Van der Heijde. “The Efficacy of Certolizumab Pegol Added to Methotrexate is Sustained Over 2 Years in the Treatment of Rheumatoid Arthritis.” In Journal of Rheumatology, 37:1332–33. J RHEUMATOL PUBL CO, 2010.
       Link to Item
    • Van Vollenhoven, Ronald, Joseph Smolen, Michael Schiff, Roy Fleischmann, Bernard Combe, Niti Goel, C. Desai, Jeffrey Curtis, and Edward Keystone. “Safety Update on Certolizumab Pegol (CZP) in Patients with Active Rheumatoid Arthritis (RA).” In Journal of Rheumatology, 37:1332–1332. J RHEUMATOL PUBL CO, 2010.
       Link to Item
    • Keystone, Edward C., Roy Fleischmann, Josef Smolen, V. Strand, Robert Landewe, Bernard Combe, Philip Mease, et al. “THE EFFICACY OF CERTOLIZUMAB PEGOL ADDED TO METHOTREXATE IS SUSTAINED OVER 2 YEARS IN THE TREATMENT OF RHEUMATOID ARTHRITIS.” In Rheumatology, 49:I105–I105. OXFORD UNIV PRESS, 2010.
       Link to Item
    • Vollenhoven, Raymond van, Josef Smolen, Michael Schiff, Roy Fleischmann, Bernard Combe, Niti Goel, Chintu Desai, et al. “SAFETY UPDATE ON CERTOLIZUMAB PEGOL (CZP) IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA).” In Rheumatology, 49:I102–3. OXFORD UNIV PRESS, 2010.
       Link to Item
    • Pope, Janet, Desiree van der Heijde, Michael Weinblatt, Robert Landewe, Niti Goel, Alvin F. Wells, and Roy M. Fleischmann. “Certolizumab Pegol Inhibits Radiographic Progression at 16 Weeks of Treatment. Results from Two RCTs (RAPID 1 And 2).” In Journal of Rheumatology, 36:2603–4. J RHEUMATOL PUBL CO, 2009.
       Link to Item
    • Heijde, Desire van der, Michael Weinblatt, Robert B. Landewe, Niti Goel, Alvin F. Wells, and Roy M. Fleischmann. “Inhibition of progression of structural damage by week 16 with certolizumab pegol: Results from the RAPID trials.” In Arthritis and Rheumatism, 58:S529–30. WILEY-LISS, 2008.
       Link to Item
    • McNearney, T. A., M. Fischbach, J. D. Reveille, N. Goel, J. R. Lisse, C. Ahn, F. C. Arnett, C. Feghali, and M. D. Mayes. “Early pulmonary involvement in systemic sclerosis: Associations with genetic, serologic, sociodemographic and behavioral factors in the GENISOS cohort..” In Arthritis and Rheumatism, 52:S172–S172. WILEY-BLACKWELL, 2005.
       Link to Item
    • Goel, N., C. H. Orces, and S. Lee. “Hip fracture trends from 1990-2001: Indirect evidence of improved diagnosis and treatment.” In Journal of Bone and Mineral Research, 19:S428–S428. AMER SOC BONE & MINERAL RES, 2004.
       Link to Item
    • McNearney, T. A., A. Shepherd, A. Chhabra, and N. Goel. “Diagnosis and treatment of postmenopausal osteoporosis: Factors influencing house staff decision-making in primary care clinics..” In Arthritis and Rheumatism, 48:S634–S634, 2003.
       Link to Item
    • McNearrey, T. A., A. Shepherd, A. Chhabra, and N. Goel. “Diagnosis and treatment of postmenopausal osteoporosis: Factors influencing house staff decision-making in primary care clinics..” In Arthritis and Rheumatism, 48:S634–35. WILEY-LISS, 2003.
       Link to Item
    • Rojas-Fernandez, C. H., K. A. Howard, and N. Goel. “Patterns of anti-osteoporotic drug use among older community dwelling west Texans and associated factors..” In Pharmacotherapy, 22:1340–1340. PHARMACOTHERAPY PUBLICATIONS INC, 2002.
       Link to Item
    • Chhabra, A., T. McNearney, A. J. Shepherd, N. Hussain, and N. Goel. “Primary care resident evaluations for chronic health conditions: A failure to assess for osteoporosis.” In Journal of Bone and Mineral Research, 17:S204–S204. AMER SOC BONE & MINERAL RES, 2002.
       Link to Item
    • Chhabra, K., T. A. McNearney, A. Shepherd, N. Hussain, and N. Goel. “Low priority of diagnostic screening of osteoporosis by primary care residents..” In Arthritis and Rheumatism, 46:S97–S97. WILEY, 2002.
       Link to Item
    • King, A. B., K. Saag, R. T. Burge, E. P. Balda, M. Pisu, and N. Goel. “The budget impact of current bone mineral density testing rates in the medicare program..” In Arthritis and Rheumatism, 46:S583–S583. WILEY, 2002.
       Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.